We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    corticosteroids | Sickle Cell Disease

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (IMPROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02061202
Recruitment Status : Completed
First Posted : February 12, 2014
Results First Posted : March 11, 2019
Last Update Posted : March 11, 2019
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai

Brief Summary:
The proposed research is designed to test the global hypothesis that inhaled corticosteroids (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in adults with Sickle Cell Disease (SCD) who wheeze, but do not meet criteria for a diagnosis of asthma. The specific aims of this proposal are 1) Conduct a feasibility study - a randomized controlled trial of ICS for adults with SCD who do not meet criteria for a diagnosis of asthma but report recurrent cough or wheezing, 2) Measure the effects of ICS on biological correlates of pulmonary inflammation (as determined by exhaled nitric oxide) and vascular injury (as determined by sVCAM) in SCD, and 3) Compare properties of traditional and Bayesian adaptive clinical trial design for therapeutic trials in SCD in preparation for designing a definitive trial of ICS. These aims have the potential to 1) change the standard of care for individuals with SCD and recurrent cough or wheeze, 2) provide insight into the pathogenesis of non-asthmatic wheezing in SCD and its response to treatment, 3) explore the suitability of innovative clinical trial designs to overcome the challenges that have hindered therapeutic innovation for SCD.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Mometasone Furoate Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Inhaled Mometasone to Promote Reduction in Vasoocclusive Events
Study Start Date : March 2014
Actual Primary Completion Date : November 2017
Actual Study Completion Date : November 2017

Arm Intervention/treatment
Experimental: Mometasone Furoate
1 puff daily (220mcg) for 16 weeks
Drug: Mometasone Furoate
inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks

Placebo Comparator: Placebo
1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
Drug: Placebo
placebo training inhaler with the same instructions as the experimental group.

Primary Outcome Measures :
  1. Number of Participants Who Completed Follow up [ Time Frame: at 2 years ]
    Feasibility is determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled.

Secondary Outcome Measures :
  1. Change in Exhaled Nitric Oxide (eNO) [ Time Frame: Before ICS therapy begins and at 8 weeks post enrollment ]
    Change in effects of inhaled corticosteroids (ICS) as measured by exhaled nitric oxide levels, which is the primary marker of pulmonary inflammation.

  2. Change in Soluble Vascular Cell Adhesion Molecule (sVCAM) Level [ Time Frame: Before ICS therapy begins and at 8 weeks post enrollment ]
    Mean Change in effects of inhaled corticosteroids vascular injury, assessed by biomarker sVCAM as a surrogate for vascular injury.

  3. Change in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) [ Time Frame: baseline and week 20 ]
    Mean changes in ASCQ-Me (NHLBI developed a patient-reported Sickle Cell Disease (SCD) quality of life measurement tool) pain impact, at week 20 as compared to baseline. A reduction change on a 100-point scale indicated improved quality of life. ASCQ-Me uses a T-score metric (0-100) in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.

  4. The Medication Adherence Report Scale [ Time Frame: 20 weeks ]
    The medication adherence report scale for asthma is a 10 question tool scored between 0 and 5, with full scale from 0 to 25, with higher scores indicating greater adherence

  5. Change in the Numerical Rating Scale (NRS) for Pain [ Time Frame: baseline and 20 weeks ]
    Mean change in patient reported pain NRS score, full scale range 0- 10, higher score indicate more pain

  6. Asthma Control Test [ Time Frame: 8 weeks ]
    Asthma control test, total score from 0-25, with higher score indicating more symptoms

  7. Admissions or Visits to the Hospital [ Time Frame: baseline through 8 weeks ]
    Number of times participant visited the Emergency Department (ED) or was admitted to the hospital

  8. Change in Reticulocytes Count [ Time Frame: baseline and 8 weeks ]
    Mean change in reticulocytes count - the number of new red blood cells.

  9. Change in FEV1/FVC [ Time Frame: baseline and 8 weeks ]
    Mean change in FEV1/FVC at 8 weeks compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 15 or older
  • Sever SCD phenotypes (Hb SS and Sβthalassemia0)
  • A positive response to cough/wheeze questions

Exclusion Criteria:

  • Patient carries a physician diagnosis of asthma
  • Patient is prescribed asthma medications
  • Patient is currently having a painful crisis (as defined by validated pain diary questions)
  • Patient has acute respiratory symptoms
  • Known hypersensitivity to milk proteins
  • Meets criteria for our operational diagnosis of asthma
  • More than 15 ED visits for pain over the preceding 12 months
  • Admitted or discharged from the hospital for SCD pain within the last 7 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02061202

Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Jeffrey Glassberg
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Jeffrey Glassberg, MD, MA Icahn School of Medicine at Mount Sinai
  Study Documents (Full-Text)

Documents provided by Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jeffrey Glassberg, Assistant Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT02061202    
Other Study ID Numbers: GCO 12-1565
K23HL119351 ( U.S. NIH Grant/Contract )
First Posted: February 12, 2014    Key Record Dates
Results First Posted: March 11, 2019
Last Update Posted: March 11, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai:
Sickle Cell Disease
Pain Crisis
Painful Crisis
Sickle Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hematologic Diseases
Genetic Diseases, Inborn
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents